#Regeneron's COVID-19 antibody cocktail curbs virus, speeds recovery in early data
“REGN-COV2” #REGNCOV2
Analysts at Jefferies said these data suggest this therapy “could provide an option to help bridge until vaccines are available” and may also show that vaccines generating similar antibody responses "may provide protection.”
Jefferies added that according to conversations “between our US biotech colleagues and Regeneron management,” the company is debating whether to continue with both dose arms (2.4 g and 8 g) or only the low-dose arm (2.4 g).
The analysts were a little more cautious than Evercore’s, and said that while Regeneron is “encouraged,” it remains to be determined whether the data set is deemed good enough by the FDA to nab an emergency nod.
This is also good news for Swiss major #Roche, which has a deal to distribute the drug outside the U.S.
No comments:
Post a Comment